Prescription drug · ANDA
Darifenacin NDC 33342-276
Darifenacin hydrobromide 7.5 mg/1 · Tablet, Extended release · Oral · Macleods Pharmaceuticals Limited
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 33342-276-07 | 3334202760733342027607 | 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (33342-276-07)Marketed from Jul 29, 2017 | |
| 33342-276-10 | 3334202761033342027610 | 90 TABLET, EXTENDED RELEASE in 1 BOTTLE (33342-276-10)Marketed from Jul 29, 2017 | |
| 33342-276-12 | 3334202761233342027612 | 10 BLISTER PACK in 1 CARTON (33342-276-12) / 10 TABLET, EXTENDED RELEASE in 1 BLISTER PACKMarketed from Jul 29, 2017 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Darifenacin
- Generic name (nonproprietary)
- darifenacin
- Active ingredients
- Darifenacin hydrobromide — 7.5 mg/1
- Dosage form
- Tablet, Extended release
- Route
- Oral
- Labeler
- Macleods Pharmaceuticals LimitedNDC labeler code 33342
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 207302
- Marketing start
- Listing expires
- Other FDA classes
- Cholinergic Muscarinic Antagonists (Mechanism)
- Identifiers
- Product ID 33342-276_2abbe156-e5ab-484c-aed7-fa4b5f06698dSPL ID 2abbe156-e5ab-484c-aed7-fa4b5f06698dSPL set ID 7ae60119-e22c-4806-a5d8-db7c9e8984a2RxCUI 485421, 485423UNII CR02EYQ8GVUPC 0333342277077, 0333342276070, 0333342277107, 0333342276100
- Pharmacologic class
- Cholinergic Muscarinic Antagonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N433342027607followed by a unit qualifier and the quantityPackage 33342-0276-07. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Darifenacin is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Darifenacin extended-release tablet is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. ( 1 )
Excerpt only. Read the full label for complete information.
About NDC 33342-276
- What is NDC 33342-276?
- 33342-276 is the product NDC for Darifenacin, Darifenacin hydrobromide 7.5 mg/1 tablet, extended release, listed with the FDA by Macleods Pharmaceuticals Limited. It has 3 package NDCs, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Darifenacin.
- What is the active ingredient?
- Darifenacin hydrobromide.
- Who is the labeler?
- Macleods Pharmaceuticals Limited, NDC labeler code 33342. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Darifenacin?
- 15 other product NDCs are listed under this name. See all Darifenacin NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Darifenacin products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Darifenacin | Darifenacin hydrobromide 7.5 mg/1 | Tablet, Extended releaseOral | Alembic Pharmaceuticals Limited | 46708-223 | 46708-0223-0846708-0223-3046708-0223-90+1 more |
| Darifenacin | Darifenacin hydrobromide 15 mg/1 | Tablet, Extended releaseOral | Alembic Pharmaceuticals Limited | 46708-224 | 46708-0224-0846708-0224-3046708-0224-90+1 more |
| Darifenacin | Darifenacin hydrobromide 7.5 mg/1 | Tablet, Extended releaseOral | Alembic Pharmaceuticals Inc. | 62332-223 | 62332-0223-0862332-0223-3062332-0223-90+1 more |
| Darifenacin | Darifenacin hydrobromide 15 mg/1 | Tablet, Extended releaseOral | Alembic Pharmaceuticals Inc. | 62332-224 | 62332-0224-0862332-0224-3062332-0224-90+1 more |
| Darifenacin | Darifenacin hydrobromide 15 mg/1 | Tablet, Extended releaseOral | Macleods Pharmaceuticals Limited | 33342-277 | 33342-0277-0733342-0277-1033342-0277-12 |
| Darifenacin | Darifenacin hydrobromide 7.5 mg/1 | Tablet, Extended releaseOral | Torrent Pharmaceuticals Limited | 13668-202 | 13668-0202-0513668-0202-3013668-0202-90 |
| Darifenacin | Darifenacin hydrobromide 15 mg/1 | Tablet, Extended releaseOral | Torrent Pharmaceuticals Limited | 13668-203 | 13668-0203-0513668-0203-3013668-0203-90 |
| Darifenacin | Darifenacin hydrobromide 7.5 mg/1 | Tablet, Extended releaseOral | Bryant Ranch Prepack | 72162-2570 | 72162-2570-03 |
| Darifenacin | Darifenacin hydrobromide 15 mg/1 | Tablet, Extended releaseOral | Bryant Ranch Prepack | 72162-2571 | 72162-2571-03 |
| Darifenacin | Darifenacin hydrobromide 7.5 mg/1 | Tablet, Film coated, Extended releaseOral | Rising Pharma Holdings, Inc. | 16571-767 | 16571-0767-0316571-0767-09 |
Other NDCs under ANDA 207302
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Darifenacin | Darifenacin hydrobromide 15 mg/1 | Tablet, Extended releaseOral | Macleods Pharmaceuticals Limited | 33342-277 |